###begin article-title 0
###xml 60 68 <span type="species:ncbi:9606">Patients</span>
IL-7 Up-Regulates TNF-alpha-Dependent Osteoclastogenesis in Patients Affected by Solid Tumor
###end article-title 0
###begin p 1
Conceived and designed the experiments: IR RF. Performed the experiments: IR EG LB. Analyzed the data: IR GB EG MG SC RF. Contributed reagents/materials/analysis tools: LB RM ER DO LC AM. Wrote the paper: IR GB MG RF.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 167 172 <span type="species:ncbi:9606">human</span>
Interleukin-7 (IL-7) is a potent regulator of lymphocyte development, which has also significant effects on bone; in fact it is a potent osteoclastogenic factor. Some human solid tumors produce high IL-7 levels, suggesting a potential IL-7 role on tumor development and progression.
###end p 3
###begin title 4
Methodology
###end title 4
###begin p 5
###xml 19 27 <span type="species:ncbi:9606">patients</span>
We studied 50 male patients affected by solid tumors, and their blood samples were collected at tumor diagnosis. PBMCs were isolated and cultured with/without IL-7 to study its influence on osteoclastogenesis. Serum and cell culture supernatant IL-7 levels were measured by ELISA. The quantitative analysis of IL-7 expression on T and B cells was performed by Real-Time PCR.
###end p 5
###begin title 6
Principal Findings
###end title 6
###begin p 7
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Serum IL-7 levels were highest in osteolytic cancer patients, followed by cancer patients without bone lesions, and then healthy controls. We showed the IL-7 production in PBMC cultures and particularly in monocyte and B cell co-cultures. A quantitative analysis of IL-7 expression in T and B cells confirmed that B cells had a high IL-7 expression. In all cell culture conditions, IL-7 significantly increased osteoclastogenesis and an anti-IL-7 antibody inhibited it. We demonstrated that IL-7 supports OC formation by inducing the TNF-alpha production and low RANKL levels, which synergize in promoting osteoclastogenesis.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
We demonstrated the presence of high serum IL-7 levels in patients with bone metastasis, suggesting the use of serum IL-7 level as a clinical marker of disease progression and of bone involvement. Moreover, we showed the capability of IL-7 to stimulate spontaneous osteoclastogenesis of bone metastatic patients and to induce osteoclastogenesis in cancer patients without bone involvement. These findings add further details to the disclosure of the mechanisms controlling bone metastasis in solid tumors.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 143 146 143 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Appasamy1">[1]</xref>
###xml 352 355 352 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Fry1">[2]</xref>
###xml 469 472 469 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-AlRawi1">[3]</xref>
###xml 474 477 474 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-AlRawi2">[4]</xref>
###xml 636 639 636 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Eder1">[5]</xref>
###xml 641 644 641 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Foss1">[6]</xref>
###xml 784 787 784 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Sharma1">[7]</xref>
###xml 1074 1077 1074 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-AlRawi2">[4]</xref>
###xml 1158 1161 1158 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Maeurer1">[8]</xref>
###xml 1169 1172 1169 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Trinder1">[9]</xref>
###xml 1214 1218 1214 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Cosenza1">[10]</xref>
###xml 388 393 <span type="species:ncbi:9606">human</span>
###xml 1045 1053 <span type="species:ncbi:9606">patients</span>
Interleukin-7 (IL-7) is a pleiotropic immune regulatory protein predominantly produced by stromal cells and by cells at the inflammatory sites [1]. IL-7 is fundamental for the early development of lymphocytes and is a regulator of peripheral T cell homeostasis by modulating the expansion of peripheral T-cell populations in states of T cell depletion [2]. The production of IL-7 by some human solid tumors suggests its potential impact on the process of tumorigenesis [3], [4], but it is unclear how IL-7 is involved in solid tumor development and progression. IL-7 stimulates the progression of some types of lymphomas and leukaemias [5], [6] and in non-small cell lung cancer, it was reported that IL-7 targeted gene therapy may be effective in modifying host anti-tumor responses [7]. Recent studies on breast cancer describe a quantitative association between the IL-7 signalling complex and some clinico-pathological parameters: there is a trend towards a higher expression of IL-7 and molecules of its signalling pathway in breast cancer patients with poor prognosis [4]. Moreover, IL-7/IL-7R mRNA was detected in different tumors, such as colorectal [8], renal [9], lung and central nervous system cancers [10].
###end p 11
###begin p 12
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Lee1">[11]</xref>
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Miyaura1">[12]</xref>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Boyle1">[13]</xref>
###xml 448 452 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Azuma1">[14]</xref>
###xml 454 458 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Roato1">[15]</xref>
###xml 596 600 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Weitzmann1">[16]</xref>
###xml 752 756 736 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Weitzmann2">[17]</xref>
###xml 758 762 742 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Roggia1">[18]</xref>
###xml 715 721 <span type="species:ncbi:10090">murine</span>
IL-7 is involved in the control of osteoclastogenesis, however depending on the model considered, it displays either an inhibitory or an activator effect on OCs [11], [12]. The OCs derive from cells of the monocytic-macrophagic lineage, which fuse to form bone-resorbing cells in the presence of Macrophage Colony Stimulating Factor (M-CSF) and Receptor Activator of Nuclear factor kB Ligand (RANKL) [13] or Tumor Necrosis Factor-alpha (TNF-alpha) [14], [15]. Weitzmann et al. demonstrated that systemic administration of IL-7 stimulates osteoclastogenesis through T cells by RANKL and TNF-alpha [16]. In addition, they showed that TNF-alpha produced by T cells synergises with RANKL increasing bone destruction in murine models of estrogen deficiency [17], [18].
###end p 12
###begin p 13
###xml 483 487 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Roato1">[15]</xref>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
The addition of exogenous cytokines is necessary to stimulate osteoclastogenesis in patients without osteolysis and in healthy controls. Previously, we demonstrated that peripheral blood mononuclear cells (PBMCs) from cancer patients with osteolysis differentiate spontaneously into OCs. In addition, we showed that in patients with osteolysis the activation of osteoclastic precursors depends on circulating tumor cells or on factors released from the tumor site, such as TNF-alpha [15].
###end p 13
###begin p 14
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Giuliani1">[19]</xref>
###xml 293 297 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Okopien1">[21]</xref>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
To better identify the factors involved in the spontaneous osteoclastogenesis, present in bone metastatic patients, we focused our studies on IL-7, since it have been associated with haematological malignancies and inflammatory diseases characterized by a local and/or systemic bone loss [19]-[21].
###end p 14
###begin p 15
###xml 102 110 <span type="species:ncbi:9606">patients</span>
IL-7 involvement in the bone metastasis formation and in the spontaneous osteoclastogenesis of cancer patients adds a further detail to the mechanisms of bone resorption and might be useful to design novel therapeutic approaches for treatment and prevention of bone metastasis.
###end p 15
###begin title 16
Results
###end title 16
###begin title 17
###xml 64 72 <span type="species:ncbi:9606">patients</span>
IL-7 levels dosed in supernatants and sera are higher in cancer patients than in healthy controls
###end title 17
###begin p 18
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 232 239 232 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g001">Fig. 1A</xref>
###xml 673 674 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 34 41 <span type="species:ncbi:9606">patient</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
###xml 953 961 <span type="species:ncbi:9606">patients</span>
We measured the IL-7 levels in 25 patient and healthy control PBMC supernatants, collected at days 5 and 10 of culture. We observed that IL-7 levels were significantly higher in patients than in healthy controls at day 5, p<0,0006 (Fig. 1A). At day 10, the IL-7 concentration was comparable to the one at day 5, both in patients and in healthy controls (data not shown). To identify the IL-7 source we performed co-colture experiments of monocytes plus B or T cells and we measured its levels in supernatants at day 5 and 10. We showed that IL-7 levels were significantly higher in cancer patients' co-coltures of both monocytes plus T or B cells than in healthy controls (p<0,0006) and remained nearly steady between day 5 and 10. In our model, the purified B cell population is responsible for IL-7 production: co-coltures of monocytes and B cells showed the highest IL-7 levels. Both in PBMC cultures and in monocytes plus T and B cells derived from patients without bone lesions we measured low levels of IL-7, comparable to healthy controls.
###end p 18
###begin p 19
###xml 133 140 133 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g001">Fig. 1B</xref>
###xml 294 295 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 696 697 690 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 242 250 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
Besides, we tested serum levels of IL-7 in 50 patients affected by solid tumors with or without metastasis at the time of diagnosis. Fig. 1B showed that IL-7 serum levels were significantly higher in patients with bone metastasis compared to patients without bone lesions and healthy controls, p<0,0001. The mean IL-7 value was 17,68+/-1,24 pg/ml for osteolytic patients, 10,73+/-0,10 pg/ml for patients without bone lesion and 5,56+/-0,30 pg/ml for healthy controls. We examined the potential differences in serum IL-7 levels according to the various types of tumor and specifically we considered prostate cancer, NSCLC and SCLC. We identified significant differences in the mean value of IL-7 (p</=0,02), which were 19.89+/-6.30 pg/ml for prostate cancer, 14.6+/-5.95 pg/ml for NSCLC and 7.56+/-4.09 pg/ml for SCLC.
###end p 19
###begin title 20
Evaluation of IL-7 expression in T and B cells with (RQ-PCR)
###end title 20
###begin p 21
###xml 234 240 234 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g002">Fig. 2</xref>
###xml 674 680 674 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g002">Fig. 2</xref>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
###xml 442 450 <span type="species:ncbi:9606">patients</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 632 640 <span type="species:ncbi:9606">patients</span>
We analysed the expression of IL-7 on freshly purified T and B cells by RQ-PCR. The analyzed transcripts exhibited high linearity amplification plots (r>0.99) and the efficiencies of both PCR reactions were quite similar. As shown in Fig. 2, we did not measure significant differences in the expression of IL-7 in both patients and healthy controls' T cells, while in healthy controls' B cells the IL-7 expression was five-fold lower than in patients. The relative expression of IL-7 was seven-fold higher in B cells than in T cells in cancer patients. We did not appreciate any significant differences in IL-7 expression in cancer patients with or without bone metastasis (Fig. 2).
###end p 21
###begin title 22
Effects of IL-7 on osteoclastogenesis
###end title 22
###begin p 23
###xml 137 152 137 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g003">Fig. 3A&#8211;B lines</xref>
###xml 424 425 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 504 511 504 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g003">Fig. 3C</xref>
###xml 663 664 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 671 678 671 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g003">Fig. 3D</xref>
###xml 734 735 730 731 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sub>
###xml 739 740 732 733 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 830 831 819 820 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sub>
###xml 835 836 821 822 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 850 857 836 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g003">Fig. 3E</xref>
###xml 102 109 <span type="species:ncbi:9606">patient</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
The OC differentiation was verified by the presence of multinucleated/TRAP positive cells from cancer patient and healthy control PBMCs (Fig. 3A-B lines, respectively). PBMCs were cultured at different doses of IL-7, that resulted in significantly increased osteoclastogenesis with 2,5 and 10 ng/ml of IL-7 in osteolytic patients and in osteoclastogenesis stimulation for patients without bone lesions and healthy controls, p<0,0001. At 15 ng/ml, IL-7 had not a stimulatory effect on osteoclastogenesis (Fig. 3C). By adding a neutralizing anti-IL-7 antibody on osteolytic patients' PBMC, we observed a dose-dependent inhibition of spontaneous osteoclastogenesis, p<0,01 (Fig. 3D). We characterized OCs also for the expression of alphaVbeta3, a typical OC marker. Both OCs derived from culture with and without IL-7 expressed alphaVbeta3, as shown in Fig. 3E.
###end p 23
###begin p 24
###xml 613 614 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 722 729 722 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g004">Fig. 4A</xref>
###xml 864 871 864 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g004">Fig. 4B</xref>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 482 490 <span type="species:ncbi:9606">patients</span>
###xml 948 956 <span type="species:ncbi:9606">patients</span>
The ability of IL-7 to induce OC formation was tested in cultures of purified monocytes alone and in co-cultures with purified T or B cells treated or untreated with IL-7 at 2,5 and 15 ng/ml. Our results showed that monocytes alone were not able to support significant OC formation in either the presence or absence of IL-7, in both cancer patients and healthy controls (data not shown). Moreover, we demonstrated that co-cultures of monocytes and T cells both from bone metastatic patients and healthy controls resulted in a significant induction of OC formation by adding 2,5 ng/ml compared to basal condition, p < 0,001, while the dose of 15 ng/ml did not elicit a significant stimulatory effect on osteoclastogenesis (Fig. 4A). Co-cultures of monocytes and B cells in presence of IL-7 showed an increase in OC number, but it was not statistically significant (Fig. 4B). In all culture conditions, we observed a comparable osteoclastogenesis in patients without bone metastases and in healthy controls (data not shown).
###end p 24
###begin p 25
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Roato1">[15]</xref>
Since we showed that spontaneous osteoclastogenesis depends on contact between monocytes and lymphocytes [15], we investigated whether T and B cells were necessary for IL-7-dependent OC differentiation. We cultured purified monocytes with IL-7-treated conditioned medium from T and B cells and we did not observe OC differentiation (data not shown). Thus, cell-to-cell interaction between lymphocytes and monocytes are required for solid tumor dependent osteoclastogenesis.
###end p 25
###begin title 26
IL-7 stimulates OC resorbing activity
###end title 26
###begin p 27
###xml 386 401 386 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g005">Fig. 5A&#8211;B lines</xref>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 533 534 533 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 545 552 543 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g005">Fig. 5C</xref>
###xml 703 704 701 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 714 721 710 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g005">Fig. 5C</xref>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
Since we showed that IL-7 had effects in stimulating osteoclastogenesis, we verified whether there was a similar stimulatory action on bone resorbing activity. By analysing the resorption area on biocoated slices, we demonstrated that in presence of IL-7 at 2,5 ng/ml the OCs increased the bone resorbing activity of osteolytic patients and stimulated the healthy controls' resorption (Fig. 5A-B lines, respectively). The basal resorption activity of OCs derived from patients was significantly higher compared to healthy controls, #p</=0,0001 (Fig. 5C). After stimulation with IL-7 at 2,5 ng/ml, the bone resorbing activity of OCs was significantly augmented both in patients and in healthy controls, *p</=0,002 (Fig. 5C). At 15 ng/ml of IL-7, we did not observe any statistically significant variation on bone resorbing areas.
###end p 27
###begin title 28
IL-7 affects TNF-alpha and RANKL release in culture
###end title 28
###begin p 29
###xml 280 281 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 289 296 281 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g006">Fig. 6A</xref>
###xml 510 511 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 518 525 502 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g006">Fig. 6B</xref>
###xml 653 662 633 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g006">Fig. 6A&#8211;B</xref>
###xml 905 906 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 915 922 885 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g006">Fig. 6C</xref>
We assessed the IL-7 ability to induce TNF-alpha and RANKL secretion in PBMC cultures and monocyte plus T or B cell co-coltures at day 5 and 10. The basal levels of TNF-alpha were similar in PBMC media at day 5 and 10 and they significantly increased by adding 2,5 ng/ml of IL-7, p<0,002 (Fig. 6A). Co-cultures of monocytes and T or B cells showed basal TNF-alpha levels higher at day 10 than at day 5. Monocytes plus T cells displayed an IL-7 dose-dependent increase of TNF-alpha level both on days 5 and 10, p<0,01 (Fig. 6B). At 15 ng/ml of IL-7, TNF-alpha values reached a plateau level both in PBMC cultures and in monoytes plus T cell co-coltures (Fig. 6A-B). At day 5, co-coltures of monocytes and B cells showed a significant enhancement of TNF-alpha amount at 15 ng/ml, whereas at day 10 we measured a significant increase in TNF-alpha levels at 2.5 ng/ml, that was unchanged at 15 ng/ml of IL-7, p</=0,01 (Fig. 6C).
###end p 29
###begin p 30
###xml 216 223 216 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000124-t001">Table 1</xref>
###xml 622 629 610 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g007">Fig. 7A</xref>
###xml 646 653 634 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000124-g007">Fig. 7B</xref>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
We found low RANKL levels in culture media collected from PBMC and monocyte plus T or B co-coltures. In particular, in the IL-7 treated cells there were not significant differences compared to unstimulated controls (Table 1). To further study the involvement of TNF-alpha and RANKL we cultured cancer patients' PBMC in presence of IL-7 and a neutralizing anti-TNF-alpha antibody or osteoprotegerin (OPG) in different concentrations. Both the inhibitors determined a dose-dependent inhibition of bone resorbing activity (data not shown) and of osteoclastogenesis, that was stronger in cultures treated with anti-TNF-alpha (Fig. 7A) than with OPG (Fig. 7B). Thus, our data demonstrated that IL-7 supports osteoclastogenesis by inducing mainly the TNF-alpha production and low levels of RANKL.
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Miyaura1">[12]</xref>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Weitzmann3">[22]</xref>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-DAmelio1">[23]</xref>
###xml 297 301 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Okopien1">[21]</xref>
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Szepietowski1">[24]</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Wasilewska1">[25]</xref>
###xml 362 366 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Weitzmann3">[22]</xref>
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Cenci1">[26]</xref>
###xml 961 965 961 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Chopra1">[27]</xref>
###xml 966 970 966 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Chopra3">[29]</xref>
###xml 1099 1103 1099 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Giuliani1">[19]</xref>
###xml 1126 1130 1126 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-vanRoon1">[30]</xref>
###xml 1174 1178 1174 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-DeBenedetti1">[31]</xref>
###xml 2139 2142 2139 2142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-AlRawi2">[4]</xref>
###xml 2144 2147 2144 2147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Maeurer1">[8]</xref>
###xml 2149 2153 2149 2153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Cosenza1">[10]</xref>
###xml 2277 2280 2277 2280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Foss1">[6]</xref>
###xml 2282 2286 2282 2286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Giuliani1">[19]</xref>
###xml 2288 2292 2288 2292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-DAmelio1">[23]</xref>
###xml 2294 2298 2294 2298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Long1">[32]</xref>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
###xml 649 657 <span type="species:ncbi:9606">patients</span>
###xml 778 786 <span type="species:ncbi:9606">patients</span>
###xml 892 900 <span type="species:ncbi:9606">patients</span>
###xml 1211 1219 <span type="species:ncbi:9606">patients</span>
###xml 1392 1400 <span type="species:ncbi:9606">patients</span>
###xml 1573 1581 <span type="species:ncbi:9606">patients</span>
###xml 1828 1836 <span type="species:ncbi:9606">patients</span>
###xml 1886 1894 <span type="species:ncbi:9606">patients</span>
Over the last years, many studies investigated the cross-talk between immune system and bone, and IL-7 appeared as an important factor in these interactions [12], [22], [23]. IL-7 is known to be a powerful inducer of T and B lymphopoiesis, moreover many studies link IL-7 to inflammatory diseases [21], [24], [25] and bone loss in estrogen deficiency conditions [22], [26]. Our study focused on IL-7 involvement in the spontaneous osteoclastogenesis occurring in cancer patients with osteolytic metastasis. We showed significantly higher IL-7 levels in supernatants derived from PBMC cultures and co-coltures of monocytes and T or B cells of cancer patients compared to healthy controls. Our data describe for the first time the presence of elevated IL-7 levels in sera of male patients affected by solid tumors, in fact the only data available in literature, concerning IL-7 serum levels in patients affected by solid tumors are related to gynecologic cancers [27]-[29], while elevated serum IL-7 levels were previously detected in other pathologies with bony involvement, such as multiple myeloma [19], rheumatoid arthritis [30] and systemic juvenile rheumatoid arthritis [31]. It is interesting to note that patients affected by bone metastatic cancer had an IL-7 value higher than non-bone metastatic ones, and these latter showed an intermediate IL-7 serum value between bone metastatic patients and healthy controls. The high IL-7 serum levels might be interpreted as a signal of disease progression towards the metastatic phenotype in some non-bone metastatic tumor patients. The analysis of the available data showed that NSCLC and prostate cancer had a statistically significant higher IL-7 serum levels compared to SCLC cases. However, in all the specific cancer groups (NSCLC, prostate cancer and SCLC) we found that patients with bone metastasis had higher IL-7 levels than patients without osteolysis. These findings might infer that in different tumor types the increase of IL-7 serum levels might be useful for early diagnosis of metastatic bone lesions. Literature data support the IL-7 production by different tumor types [4], [8], [10] apart from stromal cells in bone microenvironment. Previously reported data showing the role of B cells in IL-7 production [6], [19], [23], [32], were confirmed by our finding that B cells produced IL-7 and this production was higher than T cell one.
###end p 32
###begin p 33
###xml 635 639 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Li1">[33]</xref>
###xml 641 645 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Varas1">[34]</xref>
###xml 731 735 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Weitzmann1">[16]</xref>
###xml 737 741 733 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Giuliani1">[19]</xref>
###xml 743 747 739 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Toraldo1">[35]</xref>
###xml 1093 1097 1077 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Okopien1">[21]</xref>
###xml 1326 1330 1310 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Lam1">[36]</xref>
###xml 1332 1336 1316 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Fuller1">[37]</xref>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
In this study we demonstrated that IL-7 at 2,5 ng/ml increased osteoclastogenesis in patients' cultures of PBMCs and co-coltures of monocytes plus T or B cells, while at the dose of 15 ng/ml, IL-7 did not affect osteoclastogenesis. To explain this result we hypotesize that, at high doses, IL-7 stimulates a differentiation switch from OCs towards dendritic cells since in cultures with 15 ng/ml of IL-7 we observed only few OCs and mainly undifferentiated macrophages or cells with dendritic cells morphology. This hypothesis is supported by some studies showing that IL-7 regulates dendritic cells differentiation from PBMC cultures [33], [34]. Since literature data link IL-7 to TNF-alpha and RANKL-dependent osteoclastogenesis [16], [19], [35], we measured their levels in culture media. In detail, we showed that IL-7 enhances in a dose-dependent manner TNF-alpha levels in PBMC culture media and in co-coltures of monocytes and T or B cells. We hypothesize that TNF-alpha levels reached maximal values in the PBMC cultures probably due to a cooperative release of TNF-alpha by monocytes [21], T and B cells stimulated by IL-7. We observed a little and not statistically significant dose-dependent increase of RANKL release from day 5 to day 10 of culture compared to unstimulated condition. According to literature data [36], [37] we think that these low levels of RANKL are synergistic with TNF-alpha in promoting osteoclastogenesis. In fact we observed that both anti-TNF-alpha antibody and OPG caused a dose-dependent inhibition of IL-7-induced osteoclastogenesis. The anti-TNF-alpha antibody reached an OC inhibition plateau at 90% while OPG treatment of cell cultures reached a plateau of OC differentiation inhibition at 50%. Further increase in OPG concentrations, in an attempt to reach an higher level of inhibition, was found to be toxic for the cultured cells. This observation suggests that in our model TNF-alpha might have a stronger role in OC formation than RANKL; it is conceivable that both factors may synergize in OC differentiation.
###end p 33
###begin p 34
###xml 523 527 507 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-vanRoon1">[30]</xref>
###xml 559 563 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Theill1">[38]</xref>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
These last results demonstrate that TNF-alpha plays a fundamental role in IL-7-induced osteoclastogenesis in patients affected by solid tumor. Moreover, the pivotal role exerted by TNF-alpha in our systems was also supported by the fact that in freshly isolated T and B cells from patients we did not find RANKL expression, while TNF-alpha was strongly present. TNF-alpha enhancement by IL-7 is also present in other pathological conditions, characterized by a local and/or systemic bone loss, such as rheumatoid arthritis [30] or postmenopausal osteoporosis [38].
###end p 34
###begin p 35
###xml 394 402 <span type="species:ncbi:9606">patients</span>
In conclusion, we propose a new physiopathologic mechanism with a key role of IL-7 in the formation of solid tumor bone metastasis. We demonstrated that IL-7, produced mainly by B cells in cell culture, directly sensitizes T cells to produce pro-osteoclastogenic factors, such as TNF-alpha and RANKL, and enhances spontaneous osteoclastogenesis. It could be useful to analyse a large number of patients for each different tumor type, in order to set an IL-7 cut off value, representative of a warning threshold for clinicians. This could allow to follow the bone metastatic disease both at diagnosis and during treatments.
###end p 35
###begin title 36
Material and Methods
###end title 36
###begin title 37
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 37
###begin p 38
###xml 256 263 254 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000124-t002">Table 2</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 463 471 <span type="species:ncbi:9606">patients</span>
###xml 500 505 <span type="species:ncbi:9606">women</span>
Samples from peripheral blood (PB) were obtained from 50 male patients affected by solid tumors and 50 healthy controls, matched for age and sex. The main clinical characteristics of patients, aged from 50 to 84 years (median 65+/-11,01 SD), are listed in Table 2. The patients' samples were collected at diagnosis to exclude biases, including recent chemo/hormono-therapy and pre-existing or non-related bone pathologies. We decided not to include breast cancer patients to avoid bias deriving from women treated with steroids or hormonal therapies.
###end p 38
###begin p 39
###xml 193 201 <span type="species:ncbi:9606">patients</span>
Healthy controls showed a normal bone metabolism (evaluated by bone densitometry) and were not under medications, such as steroids that could increase osteoclastogenesis. Informed consent from patients and healthy controls was obtained to comply with institutional policies.
###end p 39
###begin title 40
Cell cultures
###end title 40
###begin p 41
###xml 935 936 923 924 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sub>
###xml 940 941 925 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 319 324 <span type="species:ncbi:9606">human</span>
###xml 590 597 <span type="species:ncbi:9606">patient</span>
PBMCs, collected from cancer patients and healthy controls, were isolated after centrifugation over a density gradient, Lymphoprep (Nycomed Pharma, Norway) and cultured in alpha-MEM, supplemented with 10% FBS, penicillin 100 U/ml and streptomycin 100 microg/m (Cambrex, Walkersville MD). To obtain fully differentiated human OCs, PBMCs were cultured with/without rhIL-7 at different doses (0,5-1-2,5-10 and 15 ng/ml), R&D Systems (Abingdon, UK). Culture supernatants were collected on days 5 and 10, when medium was either refreshed and supplemented or not with IL-7. For some experiments, patient PBMCs were cultured with different doses of anti-IL7 (50-100-300 ng/ml), R&D Systems (Abingdon, UK). Cultures were stopped after 15 days, mature OCs were identified as multinucleated cells containing three or more nuclei and positive for the expression of TRAP (Tartrate-resistant acid phosphatase, Sigma Aldrich, St. Louis MO) and alphaVbeta3 (vitronectin receptor) kindly provided by Prof. G. Tarone. To evaluate bone resorbing activity, for 21 days PBMCs were cultured on Biocoat Osteologic bone cell culture system (BD Biosciences Bedford, MA) with/without IL-7, then cells were removed and resorption lacunae were identified by light microscopy.
###end p 41
###begin p 42
For some experiments PBMCs were cultured in presence of increasing concentration of a neutralizing anti-TNFalpha (4-5 microg/ml) antibody and osteoprotegerin (OPG 10-20 ng/ml), PeproTech (London, UK).
###end p 42
###begin title 43
Isolation of monocytes, T and B cells
###end title 43
###begin p 44
###xml 355 360 <span type="species:ncbi:9606">human</span>
Monocytes, T and B cells were isolated from PBMCs by an immunomagnetic selection using MACs microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), according to the manufacturer's instructions. The purity of monocytes, T and B cells, obtained after separation, was 95-98%, as assessed by flow cytometry. Isolated cells were plated according to the human physiological concentrations: 10% monocytes and 30% lymphocytes (70% for T and 30% for B) with/without IL-7.
###end p 44
###begin title 45
ELISA (Enzyme-Linked Immunosorbent Assay)
###end title 45
###begin p 46
The amount of IL-7 in cell culture supernatant and serum was determined by ELISA kit (sensitivity was 0,156 to 20 pmol/L and 0 to 16 pmol/L, respectively. R&D Systems, Abingdon UK). TNF-alpha (Biosource, Nivelles Belgium) and RANKL (Biomedica Gruppe, Wien Austria) ELISA kit were performed on culture supernatants, the sensitivity range was 0 to 1500 pmol/L and 0 to 8 pmol/L, respectively.
###end p 46
###begin title 47
Quantitative analysis of IL-7 gene expression
###end title 47
###begin p 48
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Roato1">[15]</xref>
Total RNA was extracted from T and B cells and the first-strand cDNA synthesis was performed as previously described [15]. Quantitative analysis of IL-7 was performed with Real-Time Quantitative PCR (RQ-PCR) using beta-actin as housekeeping control. RT-PCR was carried out using the iCycler iQtrade mark system (Bio Rad, CA, USA). PCR primers and TaqMan probes were designed using Primer Express v1.0 software and synthesized by Applied Biosystems (Warrington, UK). TaqMan probe specific for IL-7 (5'-TGAGAGTGTTCTAATGGTCAGCATCGATCAAT-3') and for beta-actin (5'- CGTCACCAACTGGGACGACATGG-3') were both labelled at the 5' end with 6-carboxy fluorescein (FAM) and the 3' end with 6-carboxy-tetrametil rhodamine (TAMRA). The IL-7 primer sequences were: sense 5'-TGAAGGTAAAGATGGCAAACAA-3'; antisense 5'-CAATTTCTTTCATGCTGTCCAA-3'. The beta-actin primer sequences were: sense 5'-CCCTGAAGTACCCCATCGA-3'; antisense 5'- AAGGTGTGGTGCCAGATTTTC-3'. Reactions for IL-7 and beta-actin quantification were performed in a 25 microl final volume with 2 microl of sample cDNA, 1X iQ Supermix (Bio Rad), 0,4 microM of each primer and 0,4 microM of the IL-7 probe. The amplification conditions for quantization were: 95degreesC for 15 minutes and 50 cycles of 95degreesC for 15 seconds and 58degreesC for 1 minute.
###end p 48
###begin p 49
###xml 397 398 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 502 503 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 513 515 502 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CT</sup>
###xml 523 527 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000124-Livak1">[39]</xref>
###xml 530 531 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 604 617 593 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;CT</sup>
###xml 659 660 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 666 668 647 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
We tested a series of cell lines for the IL-7 expression and we chose , as positive control, MG63, an osteosarcoma cell line that expressed at high level IL-7. As negative control we used H522, a non-small cell lung cancer cell line. Relative IL-7 quantization in T and B lymphocytes, expressed as -fold variation over control (H522), was calculated after determination of the difference between CT (threshold cycle) of the given gene A (IL-7) and that of the calibrator gene B (beta-actin) using the 2-DeltaDeltaCT method [39]. CT values are means of duplicate measurements. To validate the use of the 2-DeltaDeltaCT method, serial dilutions (ranging from 100 to 10-5) of MG63 cDNA were used to obtained a standard curve.
###end p 49
###begin title 50
Statistical analyses
###end title 50
###begin p 51
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Statistical analyses were performed with the Statistical Package for the Social Sciences (spssx/pc) software (SPSS, Chicago, IL). We compared the results by means of student's paired t test. The results were considered statistically significant for p<0,05.
###end p 51
###begin p 52
We thank Dr. G. Giribaldi for the help in Real-Time quantitative analysis, A. Grua for computer graphics support and N. Origgi for linguistic assistance.
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
Biological and clinical implications of interleukin-7 and lymphopoiesis.
###end article-title 54
###begin article-title 55
Interleukin-7: master regulator of peripheral T-cell homeostasis?
###end article-title 55
###begin article-title 56
###xml 69 74 <span type="species:ncbi:9606">human</span>
Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours.
###end article-title 56
###begin article-title 57
###xml 74 79 <span type="species:ncbi:9606">human</span>
Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer.
###end article-title 57
###begin article-title 58
In vitro culture of common acute lymphoblastic leukemia blasts: effects of interleukin-3, interleukin-7, and accessory cells.
###end article-title 58
###begin article-title 59
Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease.
###end article-title 59
###begin article-title 60
Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity.
###end article-title 60
###begin article-title 61
Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes.
###end article-title 61
###begin article-title 62
###xml 69 74 <span type="species:ncbi:9606">human</span>
Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer.
###end article-title 62
###begin article-title 63
Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines.
###end article-title 63
###begin article-title 64
Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.
###end article-title 64
###begin article-title 65
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency.
###end article-title 65
###begin article-title 66
Osteoclast differentiation and activation.
###end article-title 66
###begin article-title 67
Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts.
###end article-title 67
###begin article-title 68
Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement.
###end article-title 68
###begin article-title 69
Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines.
###end article-title 69
###begin article-title 70
###xml 26 31 <span type="species:ncbi:9606">human</span>
T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms.
###end article-title 70
###begin article-title 71
Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo.
###end article-title 71
###begin article-title 72
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
###end article-title 72
###begin article-title 73
Rheumatoid arthritis.
###end article-title 73
###begin article-title 74
###xml 111 119 <span type="species:ncbi:9606">Patients</span>
Monocyte Release of Tumor Necrosis Factor-alpha and Interleukin-1beta in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates.
###end article-title 74
###begin article-title 75
Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency.
###end article-title 75
###begin article-title 76
###xml 89 95 <span type="species:ncbi:9606">humans</span>
Immune system and bone metabolism: Does thymectomy influence postmenopausal bone loss in humans?
###end article-title 76
###begin article-title 77
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Increased interleukin-7 levels in the sera of psoriatic patients: lack of correlations with interleukin-6 levels and disease intensity.
###end article-title 77
###begin article-title 78
###xml 79 87 <span type="species:ncbi:9606">children</span>
Relationship of serum interleukin-7 concentration and the coagulation state in children with nephrotic syndrome.
###end article-title 78
###begin article-title 79
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.
###end article-title 79
###begin article-title 80
###xml 63 71 <span type="species:ncbi:9606">Patients</span>
Angiogenin, Interleukins, and Growth-Factor Levels in Serum of Patients with Ovarian Cancer: Correlation with Angiogenesis.
###end article-title 80
###begin article-title 81
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer.
###end article-title 81
###begin article-title 82
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer.
###end article-title 82
###begin article-title 83
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis.
###end article-title 83
###begin article-title 84
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis.
###end article-title 84
###begin article-title 85
Apoptosis and interleukin 7 gene expression in chronic B-lymphocytic leukemia cells.
###end article-title 85
###begin article-title 86
###xml 87 92 <span type="species:ncbi:9606">human</span>
Effect of interleukin-7 on the in vitro development and maturation of monocyte derived human dendritic cells.
###end article-title 86
###begin article-title 87
Interleukin-7 influences the development of thymic dendritic cells.
###end article-title 87
###begin article-title 88
IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells.
###end article-title 88
###begin article-title 89
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.
###end article-title 89
###begin article-title 90
TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL.
###end article-title 90
###begin article-title 91
RANK-L and RANK: T cells, bone loss, and mammalian evolution.
###end article-title 91
###begin article-title 92
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
###end article-title 92
###begin title 93
Figures and Tables
###end title 93
###begin title 94
IL-7 levels in cell culture medium and serum.
###end title 94
###begin p 95
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
IL-7 levels in cancer patients with/without bone metastases and in healthy controls were analysed by ELISA. At day 5, supernatants of patients' PBMC cultures and monocyte plus T and B cell co-colture had IL-7 levels higher than healthy controls (A). Bone metastatic patients had significantly higher serum levels of IL-7 compared to patients without bone metastasis and healthy controls (B). Samples were assayed in duplicate and data were expressed as mean values.
###end p 95
###begin title 96
Quantitative analysis of IL-7 expression in T and B cells.
###end title 96
###begin p 97
###xml 47 60 47 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;Ct</sup>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
IL-7 expression was evaluated by RQ-PCR using 2-DeltaDeltaCt method. B cells derived from cancer patients expressed significantly higher levels of IL-7 compared to T cells. Both T and B cells from healthy controls expressed less IL-7 than patients. The control bar represents the negative control: IL-7 expression in H522 cell line. Data are means+/-SE of nine independent experiments.
###end p 97
###begin title 98
###xml 37 46 37 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro.</italic>
Effect of IL-7 on osteoclastogenesis in vitro.
###end title 98
###begin p 99
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 105 113 105 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(line A)</bold>
###xml 135 143 135 143 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(line B)</bold>
###xml 328 331 328 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 479 482 479 482 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(D)</bold>
###xml 589 590 585 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V</sub>
###xml 594 595 587 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 595 598 588 591 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(E)</bold>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
TRAP+ multinucleated cells were identified as OCs at the end of culture in both bone metastatic patients (line A) and healthy controls (line B). PBMC cultures were plated and stimulated with IL-7 (0,5-1-2,5-10-15 ng/ml). The osteoclastogenesis significantly increased at 2,5 ng/ml of IL-7 compared to the unstimulated condition (C). The anti-IL-7 antibody added in cell culture determined a dose-dependent inhibition of spontaneous osteoclastogenesis in bone metastatic patients (D). Multinucleated/TRAP positive cells, derived both from culture with and without IL-7, expressed also alphaVbeta3(E).
###end p 99
###begin title 100
IL-7 stimulates osteoclastogenesis in co-coltures of monocytes and T or B cells.
###end title 100
###begin p 101
###xml 260 263 260 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 284 287 284 287 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
The different subpopulations were isolated from PBMCs and co-coltures of monocytes and T or B cells (M+T; M+B) were made. By adding 2,5 ng/ml of IL-7 in co-coltures we observed an increase in osteoclastogenesis, which was statistically significant for T cells (A) and not for B cells (B). At 15 ng/ml of IL-7, there were not significant effects in both the co-coltures.
###end p 101
###begin title 102
IL-7 increases OC bone resorbing activity.
###end title 102
###begin p 103
###xml 84 92 84 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(line A)</bold>
###xml 114 122 114 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(line B)</bold>
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 238 239 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 249 252 247 250 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 383 384 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 393 396 389 392 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
PBMC resorption activity with/without IL-7 were showed for bone metastatic patients (line A) and healthy controls (line B). The basal resorbing activity of OCs derived from patients was significantly higher compared to healthy controls, #p</=0,0001 (C). The percentage of resorption area was significantly increased with 2,5 ng/ml of IL-7, both in patients and in healthy controls, *p</=0,002 (C). At 15 ng/ml IL-7 did not elicit a significant variation of resorption area. The data represent the means+/-SE from ten independent experiments.
###end p 103
###begin title 104
IL-7 up-regulates TNF-alpha production in cell culture media.
###end title 104
###begin p 105
###xml 272 275 264 267 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 306 309 298 301 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
###xml 343 346 335 338 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C)</bold>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
PBMC and monocytes plus T or B cells were cultured in absence or presence of IL-7. Supernatants were collected at days 5 and 10 to dose TNF-alpha. PBMCs showed the same TNF-alpha basal level, which increased at 2,5 ng/ml of IL-7 and reached the maximum value at 15 ng/ml, (A). Monocytes plus T cells (M+T) (B) and monocytes plus B cells (M+B) (C) had a TNF-alpha basal level higher at day 10 than at day 5, but both supernatants showed the peak value at 2,5 ng/ml of IL-7, and remained roughly costant at 15 ng/ml. The data were means+/-SE of 25 supernatants collected at day 5 and 10 for both patients and healthy controls.
###end p 105
###begin title 106
Effect of anti-TNF-alpha and OPG on IL-7-induced osteoclastogenesis.
###end title 106
###begin p 107
###xml 200 203 192 195 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</bold>
###xml 238 241 230 233 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B)</bold>
The addition of both OPG and anti-TNF-alpha caused a dose-dependent inhibition of IL-7-induced osteoclastogenesis. The anti-TNF-alpha antibody caused a strong osteoclastogenesis inhibition, about 90% (A) while OPG caused a 50% inhibition (B).
###end p 107
###begin title 108
RANKL levels in cell culture media.
###end title 108
###begin title 109
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics.
###end title 109
###begin p 110
TNM interantional classification: T(primary tumor), N(primary regional lymphonodes), M (metastasis), p (post-surgery)
###end p 110
###begin p 111
tumor hystologic grading
###end p 111
###begin p 112
Veterans Administration Lung Cancer Study Group (VALCSG)
###end p 112
###begin p 113
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 113
###begin p 114
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was mainly supported by a grant from Fondazione Internazionale di Ricerca in Medicina Sperimentale (FIRMS) and from Compagnia di San Paolo, "Special Project Oncology".
###end p 114

